60 Gottfried-Hagen -Straße Köln, Nordrhein-Westfalen, 51105 Germanymyotwin conducts preclinical cardiac in vitro studies using 3D engineered human myocardial tissue (eMT) derived from human induced pluripotent stem cells (hiPSCs), with expertise focused on two key areas: i) efficacy assays on cardiac disease models and ii) cardiotoxicity and safety assays including arrhythmia detection. Preclinical drug development has a myocardial stiffness blind spot. Our TrinityScreen platform records the functional outputs of i) electrophysiology, ii) calcium handling, and iii) contractility simultaneously and non-invasively on each single tissue, extrapolating the parameters of i) field potential duration, beat rate, and arrhythmic events, ii) calcium transient duration, amplitude, and kinetics, and iii) active contraction force, passive force, tissue stiffness, and contraction kinetics. Assessing active force, passive force, and stiffness in parallel makes the platform particularly relevant for cardiac fibrosis, diastolic dysfunction, and structural cardiotoxicity. myotwin's platform can be coupled with cardiac disease models such as hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), Duchenne muscular dystrophy cardiac phenotype, ischemia/reperfusion, cardiac fibrosis, arrhythmogenic cardiomyopathy, and LPS-induced cardiomyopathy. An HFpEF model is in development. We develop customized cardiac disease models tailored to the mechanism of action of our clients' therapeutic modalities, which can include small molecules, AAVs, siRNAs, LNPs, and ASOs. myotwin uses commercially available patient-derived, gene-edited, or healthy control hiPSC-CMs for its commercial projects, and eMTs can also be made from hiPSC-CMs sourced directly from our clients. In addition to its TrinityScreen platform, myotwin offers a wide range of assay readouts: quantification of cardiac biomarkers (cTnI, cTnT, NT-proBNP), viability assessment (LDH), gene expression analysis by qPCR and, through partners, RNA-seq, and detection of specific proteins and antigens via immunostaining and high content imaging. Every tissue passes quality control before our experiments. Our eMTs display adult-like functional characteristics including a positive force-frequency relationship and Frank-Starling behavior. A typical project runs about ten weeks from order to final report, and frozen tissue samples and cell culture supernatants are shipped afterwards for the client's own downstream analyses. myotwin's platform is aligned with New Approach Methodologies (NAMs). myotwin GmbH is a spin-off from the University Medical Center Göttingen, Germany.

Annastr 27 Göttingen, 37075 Germanymyotwin conducts preclinical cardiac in vitro studies using 3D engineered human myocardial tissue (eMT) derived from human induced pluripotent stem cells (hiPSCs), with expertise focused on two key areas: i) efficacy assays on cardiac disease models and ii) cardiotoxicity and safety assays including arrhythmia detection. Preclinical drug development has a myocardial stiffness blind spot. Our TrinityScreen platform records the functional outputs of i) electrophysiology, ii) calcium handling, and iii) contractility simultaneously and non-invasively on each single tissue, extrapolating the parameters of i) field potential duration, beat rate, and arrhythmic events, ii) calcium transient duration, amplitude, and kinetics, and iii) active contraction force, passive force, tissue stiffness, and contraction kinetics. Assessing active force, passive force, and stiffness in parallel makes the platform particularly relevant for cardiac fibrosis, diastolic dysfunction, and structural cardiotoxicity. myotwin's platform can be coupled with cardiac disease models such as hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), Duchenne muscular dystrophy cardiac phenotype, ischemia/reperfusion, cardiac fibrosis, arrhythmogenic cardiomyopathy, and LPS-induced cardiomyopathy. An HFpEF model is in development. We develop customized cardiac disease models tailored to the mechanism of action of our clients' therapeutic modalities, which can include small molecules, AAVs, siRNAs, LNPs, and ASOs. myotwin uses commercially available patient-derived, gene-edited, or healthy control hiPSC-CMs for its commercial projects, and eMTs can also be made from hiPSC-CMs sourced directly from our clients. In addition to its TrinityScreen platform, myotwin offers a wide range of assay readouts: quantification of cardiac biomarkers (cTnI, cTnT, NT-proBNP), viability assessment (LDH), gene expression analysis by qPCR and, through partners, RNA-seq, and detection of specific proteins and antigens via immunostaining and high content imaging. Every tissue passes quality control before our experiments. Our eMTs display adult-like functional characteristics including a positive force-frequency relationship and Frank-Starling behavior. A typical project runs about ten weeks from order to final report, and frozen tissue samples and cell culture supernatants are shipped afterwards for the client's own downstream analyses. myotwin's platform is aligned with New Approach Methodologies (NAMs). myotwin GmbH is a spin-off from the University Medical Center Göttingen, Germany.